**Name of journal:** ***World Journal of Gastroenterology***

**Manuscript NO: 40462**

**Manuscript type: ORIGINAL ARTICLE**

***Retrospective Study***

**Outcomes of furazolidone, amoxicillin-based quadruple therapy for** ***Helicobacter pylori* infection and predictors of failed eradication**

Zhang YW *et al*. Furazolidone and *H. pylori* eradication

Ya-Wen Zhang, Wei-Ling Hu, Yuan Cai, Wen-Fang Zheng, Qin Du, John J Kim, John Y Kao, Ning Dai, Jian-Min Si

**Ya-Wen Zhang,Wei-Ling Hu,Yuan Cai,Wen-Fang Zheng,Ning Dai,Jian-Min Si,**Department of Gastroenterology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310016, Zhejiang Province, China

**Ya-Wen Zhang,Wei-Ling Hu,Wen-Fang Zheng,Jian-Min Si,**Institute of Gastroenterology, Zhejiang University, Hangzhou 310016, Zhejiang Province, China

**Qin Du,**Department of Gastroenterology, Zhejiang University School of Medicine Second Affiliated Hospital, Hangzhou 310009, Zhejiang Province, China

**John J Kim,**Division of Gastroenterology, Loma Linda University Health, Loma Linda, CA 92354, United States

**John Y Kao,**Division of Gastroenterology, Department of Internal Medicine, Michigan Medicine, University of Michigan, Ann Arbor, MI 48109, United States

**ORCID number:** Ya-Wen Zhang ([0000-0002-6867-0399](http://orcid.org/0000-0002-6867-0399)); Wei-Ling Hu ([0000-0002-9145-7027](http://orcid.org/https:/orcid.org/0000-0002-9145-7027)); Yuan Cai ([0000-0003-2356-1399](http://orcid.org/https:/orcid.org/0000-0003-2356-1399)); Wen-Fang Zheng ([0000-0002-4646-0518](http://orcid.org/0000-0002-4646-0518)); Qin Du ([0000-0002-6840-8358](http://orcid.org/https:/orcid.org/0000-0002-6840-8358)); John J Kim ([0000-0003-4341-8661](http://orcid.org/0000-0003-4341-8661)); John Y Kao ([0000-0001-5338-4587](http://orcid.org/https:/orcid.org/0000-0001-5338-4587)); Ning Dai ([0000-0003-0749-9230](http://orcid.org/0000-0003-0749-9230)); Jian-Min Si ([0000-0002-1254-7949](http://orcid.org/https:/orcid.org/0000-0002-1254-7949)).

**Author contributions:** Hu WL, Zhang YW, Dai N and Si JM designed the study; Zhang YW, Cai Y and Zheng WF performed the research; Du Q contributed to provide patients support; Zhang YW and Kim JJ analyzed the data; Zhang YW wrote the paper; Kim JJ, Kao YJ and Hu WL critically revised the manuscript; all authors had access to the study data and had reviewed and approved the final version of the article.

**Supported by** the Zhejiang Science and Technology Project, No. LGF18H160012.

**Institutional review board statement:** The study was reviewed and approved by [Ethics](file:///C:\Program%20Files\Youdao\Dict\6.3.69.8341\resultui\frame\javascript:void(0);) [Committee](file:///C:\Program%20Files\Youdao\Dict\6.3.69.8341\resultui\frame\javascript:void(0);) of Sir Run Run Shaw Hospital.

**Informed consent statement:** Patients were not required to provide informed consent to the study because the data were obtained retrospectively after completing treatment.

**Conflict-of-interest statement:** The authors grants from Zhejiang Science and Technology Project during the conduct of the study and declare no other conflict of interest related to this study.

**Data sharing statement:** No additional data are available.

**Open-Access:** This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Unsolicited manuscript

**Correspondence to: Wei-Ling Hu, MD, PhD, Doctor,** Department of Gastroenterology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, No. 3 East Qingchun Road, Hangzhou 310016, Zhejiang Province, China. huweiling@zju.edu.cn

**Telephone:** +86-571-86006181

**Fax:** +86-571-86006181

**Received:** July 1, 2018

**Peer-review started:** July 2, 2018

**First decision:** July 24, 2018

**Revised:** August 16, 2018

**Accepted:** October 5, 2018

**Article in press:**

**Published online:**

**Abstract**

***AIM***

To evaluate the outcome of furazolidone, amoxicillin-based quadruple therapy for treatment of *Helicobacter pylori* (*H. pylori*) and identify predictors of failed eradication.

***METHODS***

Patients with *H. pylori* infection treated with furazolidone, amoxicillin, bismuth, and proton pump inhibitor therapy (January, 2015 to December, 2015) who received 13C-urea breath test > 4 wk after treatment were evaluated. Demographic and clinical data including prior *H. pylori* treatment attempts, medication adherence, alcohol and cigarettes consumption during therapy, and treatment-related adverse events were recorded by medical records and telephone surveys. *H. pylori* eradication rates for overall and subgroups were evaluated. Multivariate analysis was performed to identify independent predictors of failed *H. pylori* eradication.

***RESULTS***

Of the 992 patients treated and retested for *H. pylori*, the overall eradication rate was 94.5% [95% confidence interval (CI): 94.1%-95.9%]. *H. pylori* eradication rate as primary therapy was 95.0% (95%CI: 93.5%-96.5%), while as rescue therapy was 91.3% (95%CI: 86.8%-95.8%). Among the 859 patients who completed the study protocol, 144 (17%) reported treatment-related adverse events including 24 (3%) leading to premature discontinuation. In the multivariate analysis, poor medication adherence [adjusted odds ratio (AOR) = 6.7, 95%CI: 2.8-15.8], 2 or more previous *H. pylori* treatments (AOR = 7.4, 95%CI: 2.2-24.9), alcohol consumption during therapy (AOR = 4.4, 95%CI: 1.5-12.3), and possibly smoking during therapy (AOR = 1.9, 95%CI: 0.9-4.3) were associated with failed *H. pylori* eradication.

***CONCLUSION***

Furazolidone, amoxicillin-based quadruple therapy for *H. pylori* in an area with high prevalence of clarithromycin resistance demonstrated high eradication rates as primary and rescue therapies with a favorable safety profile. Patient education targeting abstinence from alcohol during therapy and strict medication adherence may further optimize *H. pylori* eradication.

**Key words:** *Helicobacter pylori*; Furazolidone; Quadruple regimen; Side effects; Eradication

**© The Author(s) 2018.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** This study examined the outcomes of furazolidone, amoxicillin-based quadruple therapy as both primary and rescue therapies for *Helicobacter pylori* (*H. pylori*) infection in nearly a thousand patients. Detailed data on adverse events and factors associated with failed *H. pylori* eradication were evaluated. Furazolidone, amoxicillin-based quadruple therapy demonstrated a high *H. pylori* eradication rate exceeding 90% with a favorable safety profile in a real-world setting. Abstinence from alcohol during therapy and strict medication adherence may further optimize eradication. The results validate guidelines recommending furazolidone-based quadruple therapy as a first-line treatment for *H. pylori* infection in areas with high prevalence of clarithromycin resistance.

Zhang YW, Hu WL, Cai Y, Zheng WF, Du Q, Kim JJ, Kao YJ, Dai N, Si JM. Outcomes of furazolidone, amoxicillin-based quadruple therapy for *Helicobacter pylori* infection and predictors of failed eradication.*World J Gastroenterol* 2018; In press

**INTRODUCTION**

*Helicobacter pylori* (*H. pylori*) is a common pathogen associated with the development of peptic ulcer disease, gastric cancer, and mucous associated lymphoid tissue lymphoma. The prevalence of *H. pylori* infection exceeds 50% worldwide, with a higher prevalence in developing countries[1,2]. Effective eradication of *H. pylori* by a combination of antimicrobial and acid suppressive therapy reduces the risk of recurrent peptic ulcers and possibly gastric cancer[3,4]. However, with the emergence of antibiotic-resistant *H. pylori* strains, traditional triple therapies have become increasingly ineffective, with some studies reporting eradication rates as low as 50%[5-8]. Selecting optimal therapies for antibiotic-resistant *H. pylori* infection has become a global public health priority.

Furazolidone is a monoamine oxidase inhibitor, nitrofurantoin-type antibiotic, commonly used in Asia. Compared to high rates of resistance observed with clarithromycin, metronidazole, and levofloxacin, *H. pylori* strains resistant to furazolidone remain uncommon[9-11]. However early animal studies demonstrating increased adverse events have limited widespread application of furazolidone in the treatment of *H. pylori*[12-16]. Given the high prevalence of *H. pylori* strains resistant to clarithromycin and metronidazole observed in recent studies, international guidelines recommend bismuth quadruple regimens that include amoxicillin, furazolidone or tetracycline for rescue therapies[17-19]. Furthermore, updated Chinese and international guidelines recommended furazolidone, amoxicillin, bismuth, and proton pump inhibitor (PPI) quadruple therapy as a first-line regimen option for *H. pylori* as primary therapy[20].

Although a number of studies with limited sample size demonstrate high efficacy of furazolidone, amoxicillin-based quadruple therapy for treatment of *H. pylori*, data on the adverse events, particularly impacting treatment course, are not well described[16]. Furthermore, predictors of failed *H. pylori* eradication other than the choice of regimen or poor medication adherence are largely unknown[16,21]. Given the high prevalence of clarithromycin-resistant *H. pylori* infection observed at our center, furazolidone, amoxicillin-based quadruple therapy has been adopted as a first-line therapy for treatment of *H. pylori* since 2013. Therefore, we performed a retrospective study of patients who received furazolidone, amoxicillin-based quadruple therapy for treatment of *H. pylori* at our center. The aim of our study was to evaluate the efficacy and safety of furazolidone, amoxicillin-based quadruple therapy as primary and rescue therapies for *H. pylori* and also to identify predictors of failed *H. pylori* eradication.

**Materials and methods**

***Study population***

Patients diagnosed with *H. pylori* at Sir Run Run Shaw Hospital (Hangzhou, China) from January 2015 to December 2015 who received furazolidone, amoxicillin-based quadruple therapy and had a follow-up *H. pylori* breath test > 4 wk after completion of therapy were evaluated. All patients who received one of two forms of direct *H. pylori* testing available at our center (13C-urea breath test or gastric biopsy) were searched, and pharmacy records were examined to identify patients who received furazolidone, amoxicillin-based quadruple therapy. All patients age ≥ 18 years who received repeat *H. pylori* breath test > 4 wk after treatment were eligible for the study. Patients who lacked repeat *H. pylori* testing to evaluate for eradication status or received therapies other than furazolidone, amoxicillin-based quadruple therapy were excluded. Medical records including endoscopy, pathology, *H. pylori* breath test, and pharmacy records were reviewed to characterize clinical course before and after *H. pylori* treatment. After the repeat breath test, all patients were seen in an outpatient visit and contacted for a detailed telephone survey. The protocol was approved by [Ethics](file:///C:\\Program%20Files\\Youdao\\Dict\\6.3.69.8341\\resultui\\frame\\javascript:void(0);) [Committee](file:///C:\Program%20Files\Youdao\Dict\6.3.69.8341\resultui\frame\javascript:void(0);) in Sir Run Run Shaw Hospital prior to initiating the study.

***H. pylori treatment***

Per hospital clinical pathway since 2013, all patients with *H. pylori* infection without contraindications to penicillin, furazolidone, bismuth, or proton pump inhibitor were treated with furazolidone, amoxicillin, bismuth, and PPI for 10-14 d of duration unless specified by the clinician. Patients were treated with furazolidone 100 mg, amoxicillin 1 g, proton pump inhibitor (esomeprazole 20 mg, rabeprazole 10 mg, pantoprazole 40 mg, lansoprazole 30 mg, or omeprazole 20 mg), and colloidal bismuth pectin (200 mg to 400 mg), and all were taken twice a day. Patients were instructed to take antibiotics immediately after meals but take PPI and bismuth 30 min before meals. Four weeks after completion of treatment, all patients were recommended to obtain a follow-up 13C-urea breath test and an outpatient consultation.

***Data collection***

Baseline data including age, gender, smoking status, alcohol status, and educational levels at the time of *H. pylori* testing as well as all prior *H. pylori* treatment attempts were recorded by reviewing medical records and telephone surveys. Endoscopy and *H. pylori* breath test reports were reviewed to obtain information on the date and indication and/or diagnosis for *H. pylori* testing. Data on *H. pylori* treatment regimens and duration were obtained by reviewing electronic pharmacy records. Data including medication adherence, potential treatment-related adverse events (dizziness, headache, fatigue, fever, anorexia, nausea, vomiting, diarrhea, constipation, abdominal discomfort or pain, bitter taste, skin rash/pruritus, weight loss, dysphagia, dyspnea, blurred vision, and myalgia), as well as, smoking and tobacco status before and during treatment were collected at the time of repeat *H. pylori* testing, outpatient consultation, or by a follow-up phone survey. In order to evaluate *H. pylori* resistance pattern, available *H. pylori* culture and antibiotic susceptibility data at the center between January 2013 and December 2014 were also collected.

***Definitions and outcomes***

The primary endpoint of the study was *H. pylori* eradication rate. Secondary endpoints were treatment-related adverse events and predictors of eradication failure. The primary endpoint was also analyzed by subgroups by patients receiving primary or rescue therapy and those with or without adverse events. Potential treatment-related adverse events were expressed as proportion of individuals experiencing a specific side effect and any side effects. Predictors of eradication failure including demographic (age, gender, educational level), clinical (number of previous treatment, indication/diagnosis of *H. pylori* testing), and treatment (PPI types, bismuth dose, treatment duration, medication adherence, smoking during treatment, alcohol use during treatment)-related factors were evaluated. Number of previous *H. pylori* treatment was categorized by none, one, or ≥ 2 prior treatment attempts. Smoking status was defined by non-smoker, abstinence during therapy, and smoking during therapy. Alcohol use was defined by no alcohol use, abstinence during therapy, and alcohol use during therapy. Educational levels were categorized by years of education (< 7, 7-9, 10-12, 13-16, or > 16 years). Poor adherence to *H. pylori* treatment was defined by patient reporting < 80% adherence of prescribed therapy[22]. Severe adverse event was defined by treatment-related adverse event necessitating discontinuation of therapy within 10 d.

***Statistical analysis***

Sociodemographic characteristics and eradication treatment (including eradication rate and side effects) data were described using number and frequency for categorical variable and mean and standard deviation for continuous variables. Eradication rate between different groups was compared using the *χ2* test. Initially, the potential association of each relevant variable with failed eradication was evaluated using the *χ2* test or Fisher’s exact test. Afterwards, variables associated with failed eradication were included in a multiple logistic regression model to evaluate for predictors of failed eradication. All statistical analyses were performed using IBM SPSS Statistics V22.0 software. Two-sided *P-*values < 0.05 were considered significant.

**RESULTS**

During the one-year study period, 992 patients were treated with furazolidone, amoxicillin-based quadruple therapy and received 13C-UBT > 4 wk after eradication (Table 1). The mean age of the patients was 46.7 ± 12.4, 501 (50.5%) were males, and 259 (26.1%) were treated for indication of peptic ulcers disease. Furthermore, 842 (84.9%) had no prior *H. pylori* treatment, 127 (12.8%) had one prior treatment, and 23 (2.3%) had ≥ 2 prior treatments. Nine hundred seventy-one (97.9%) and 21 (2.1%) patients were prescribed a 14-d regimen and a 10-d regimen, respectively. *H. pylori* culture and antibiotic susceptibility study available from 2013-2014 (*n* = 52) showed clarithromycin-resistant strains in 9 (17.3%), levofloxacin-resistant strains in 20 (38.5%), metronidazole-resistant strains in 38 (73.1%), furazolidone-resistant strains in 2 (3.8%), and none with amoxicillin-resistant strains (Supplementary Table 1).

***H. pylori eradication rate***

Of the 992 patients, 859 patients completed the study protocol.The overall eradication rate was 94.5% (95%CI: 94.1%-95.9%). *H. pylori* eradication rates were 95.0% (95%CI: 93.5%-96.5%) and 91.3% (95%CI: 86.8%-95.8%) as primary and rescue therapies, respectively. Among those who completed follow-up, patients who did not experience medication-related adverse events had a higher eradication rate (95.5% *vs* 90.3%, mean difference = 5.2%, 95%CI: 0.7%-11.7%) compared to those who experienced any reported adverse events (Table 2).

***Treatment-related adverse events***

Of the 859 patients who completed the study, 144 (16.8%) experienced one or more treatment-related adverse events (Table 3). The common adverse events including abdominal pain in 39 (4.5%), nausea in 20 (2.3%), dizziness in 11 (1.3%), fatigue in 11 (1.3%), anorexia in 13 (1.5%) and skin rash/pruritus in 18 (2.1%) were reported. Twenty-four (2.8%) patients experienced severe treatment-associated adverse events necessitating premature discontinuation of intended therapy including 10 (1.2%) who completed < 10 d of treatment. Skin rash/pruritus (*n* = 3, 0.4%) was the most common severe treatment-related adverse event.

***Predictors of failed H. pylori eradication***

On one factor analysis, the number of previous *H. pylori* treatment (78.3%-95.0%, *P* = 0.002), smoking status (88.2%-95.6%, *P* = 0.004), alcohol status (79.4%-95.5%, *P <* 0.001), and poor *H. pylori* treatment adherence (77.5% *vs* 96.2%, *P* < 0.001) were associated with failed *H. pylori* eradication (Table 4). Multivariate analysis demonstrated that ≥ 2 prior *H. pylori* treatment attempts (AOR = 7.4; 95%CI: 2.2-24.9, *P =* 0.001) compared to no treatment, and poor adherence (AOR=6.7; 95%CI: 2.8-15.8, *P* < 0.001) compared to acceptable adherence were associated with failed *H. pylori* eradication. Furthermore, alcohol use during treatment compared to non-alcohol user (AOR = 4.4; 95%CI: 1.5-12.3, *P* = 0.008), but not alcohol users abstinent during treatment (AOR = 1.0; 95%CI: 0.4-2.3, *P* = 1.00), was associated with failed *H. pylori* eradication. Finally, smoking during treatment demonstrated a trend towards failed *H. pylori* eradication (AOR = 1.9; 95%CI: 0.9-4.3, *P* = 0.10) compared to non-smokers. Age, gender, educational level, PPI type, bismuth dose, therapy duration, and the indication for treatment were not associated with failed *H. pylori* eradication.

**DISCUSSION**

In this single-center study evaluating furazolidone, amoxicillin-based quadruple therapy for *H. pylori* infection in an area with high prevalence of clarithromycin resistance, the eradication rates were high at > 90%, as both primary and rescue therapies. Furthermore, treatment-related adverse events were infrequent with fewer than 3% requiring treatment discontinuation. Poor adherence to prescribed therapy, two or more prior eradication attempts, and concurrent alcohol use during treatment were associated with failed eradication.

The rise in the prevalence of antibiotic-resistant *H. pylori* strains has led to increased treatment failure with traditional triple therapies[2,10,23]. In recognition of high global prevalence of clarithromycin- and/or metronidazole-resistant *H. pylori* infection, the updated Maastricht V/Florence Consensus Report emphasized that bismuth quadruple or non-bismuth quadruple, concomitant therapies (PPI, amoxicillin, clarithromycin and a nitroimidazole) are now the treatment of choice in regions with high (> 15%) clarithromycin and bismuth quadruple therapies are recommended in regions with high dual resistance to clarithromycin and metronidazole (> 15%)[18]. Furthermore, the guidelines recommended that clarithromycin should be avoided and a combination of antibiotics with high resistance barrier to *H. pylori* (amoxicillin, tetracycline, furazolidone, rifabutin) should be selected. The Fifth Chinese National Consensus Report recommended furazolidone, amoxicillin, bismuth, and PPI quadruple therapy as one of the first-line regimens for *H. pylori* therapy given that estimated resistance to clarithromycin and metronidazole exceed 20% and 40%, respectively, in China[20].

Our results from a real-world experience demonstrated that furazolidone, amoxicillin-based quadruple therapy achieved a 95% *H. pylori* eradication rate which is within the higher range of all eradication rates reported in the literature[16]. Although older studies mostly containing furazolidone as a component of substandard regiments (inadequate duration or absence of PPI) reported a low pooled-eradication rate of 76%, our findings are consistent with recent studies reporting high eradication rates of 85%-95% in combination with 14 d of amoxicillin[24-26]. For example, in a randomized study of 424 patients with *H. pylori* infection from Shanghai comparing four different bismuth-based quadruple therapies (amoxicillin, tetracycline, metronidazole, or furazolidone) as rescue therapy, furazolidone-containing regimens had a higher eradication rate (93.4% *vs* 85.9%; mean difference = 7.6%, 95%CI: 1.4%-13.8%) compared to non-furazolidone containing regimens per intent to treat (ITT)[24]. Furthermore, a multicenter prospective study that included 180 patients with *H. pylori*-positive duodenal ulcer allocated to amoxicillin 1 g, furazolidone 100 mg, rabeprazole 10 mg, and bismuth 220 mg twice a day for 10 d demonstrated eradication rate of 86% per ITT[26]. In another randomized controlled study comparing different duration and doses of furazolidone, 40 patients receiving furazolidone 200 mg to 300 mg per day with amoxicillin, PPI and bismuth for 2 wk led to eradication rate of 88% per ITT as rescue therapy[25]. Finally, a retrospective study of 27 United States patients receiving furazolidone-containing non-bismuth quadruple therapy for 2 wk demonstrated a high eradication rate of 97% per ITT[9]. The eradication rate of 95% in our study is remarkable, especially given that 15% of patients have experienced prior treatment failure.

The high eradication rates of *H. pylori* with furazolidone, amoxicillin-containing quadruple therapy in our study may be related to several confounding factors. First, two antibiotics (furazolidone, amoxicillin) with the highest barriers to resistance were included in the treatment regimen. With the exception to Iran where furazolidone-resistant *H. pylori* is common (5% to 22%), the reported resistance rates in China, Vietnam, and United States, are consistently < 5%[2,11,23,27-30]. A recent local study examining 545 *H. pylori* cultures obtained from children showed absence of furazolidone-resistant *H. pylori*, consistent with the low (4%) resistance rate shown at our center[29]. In addition to the low prevalence of furazolidone-resistant *H. pylori* (< 5%), amoxicillin as the backbone of eradication therapy continues to have the lowest prevalence of *H. pylori* resistance reported globally (< 1%-2%) and in China (< 5%). Second, bismuth that has been shown to improve treatment eradication rate by 30%-40% in areas with high prevalence of *H. pylori* resistance was routinely added in our study[31]. Third, almost all (98%) patients received a 14-d regimen and none of the patients were prescribed < 10 d of intended therapy. Although the results are inconsistent, systemic review of 75 studies demonstrated that longer duration of therapy improves eradication and 14 d of treatment have been recommended by updated guidelines[18,32,33]. Finally, selection bias favoring higher eradication rate is possible among population returning for confirmatory *H. pylori* testing.

Our study demonstrated that adverse events occurred in 17% (95%CI: 14.3%-19.3%) of the cohort with premature discontinuation of therapy occurring in 2.8% (95%CI: 1.7%-3.9%). The adverse events (abdominal discomfort, dizziness, nausea, fatigue, anorexia, rash, pruritus) observed in our study were mild and non-specific, similar to other studies evaluating furazolidone-containing regimens[34]. Furthermore, all side effects resolved after completion or withdrawal of therapy without any documented events of severe hepatotoxicity or kidney injury. Although the incidence of adverse events with furazolidone-containing *H. pylori* regimen is common (18%-33%)[16,25],the incidence of adverse events associated with furazolidone-containing regiment are not elevated compared to amoxicillin-based triple or tetracycline and metronidazole-based quadruple therapy[24]. A Chinese meta-analysis of 788 patients also demonstrated no difference in the incidence of adverse events between furazolidone-containing quadruple therapy compared to other quadruple therapy regimens as rescue therapy (14.1% *vs* 13.8%; OR = 1.04, 95%CI: 0.7-1.6)[35]. The incidence of furazolidone associated adverse events is dose-dependent and more severe among those treated with high (400 mg per day) compared to low-dose furazolidone (200 mg per day), longer duration, and co-therapy with bismuth. Low-dose furazolidone studies generally demonstrate a low incidence of adverse events of < 20%[36-39]. Although the eradication rate of patients with adverse events was lower (90.3% *vs* 95.5%, mean difference = -5.2%, 95%CI: -0.7% to -11.7%) compared to those without adverse events in our study, the overall eradication rate remained high at > 90%.

Furazolidone is a synthetic nitrofuran that has been widely used as an antibiotic to treat enteric infections globally. The carcinogenetic effects of furazolidone suggested in early animal studies[12-15,40] have remained speculative in clinical settings. Furazolidone is a category 3 agent and considered unclassifiable in regards to carcinogenicity in humans[41]. Despite being a widely used antibiotic in Asia for more than two decades, teratogenicity or carcinogenicity in humans has yet to be reported despite close scrutiny[42]. Furazolidone is currently not available in the United States due to the lack of a commercial market[43]. The abandonment of furazolidone-based therapy of finite duration due to concerns of side effects may be misguided[43]. Our current study of nearly one thousand patients demonstrating favorable safety profile supports the use of low-dose furazolidone-based quadruple therapy for *H. pylori* infection.

Multivariate analysis demonstrated that poor adherence (AOR = 6.7, 95%CI: 2.8-15.8), history of multiple treatment failures (AOR = 7.4, 95%CI: 2.2-24.9), alcohol use (AOR = 4.4, 95%CI: 1.5-12.3), and possibly smoking (AOR = 1.9, 95%CI: 0.9-4.3) during therapy were associated with failed *H. pylori* eradication. As expected and consistent with previous findings, poor adherence defined by taking < 80% of the prescribed therapy and history of multiple treatment failures defined by ≥ 2 treatment attempts had more than 6-fold and 7-fold increased risks of treatment failure, respectively[44,45]. Concurrent alcohol, but not alcohol abstinence during therapy, compared to non-alcohol use increased the odds of treatment failure in our study. Although the reason is unclear, concurrent alcohol use with furazolidone may lead to increased adverse events that may impact adherence to therapy. Smoking has been previously associated with decreased *H. pylori* eradication rate with proposed reasons including adverse impact on adherence, decreased gastric mucosal blood flood, increased gastric acidity, and altered PPI metabolism[46,47].

Our findings have clinical implications. Rather than pathogen associated-factors, host-associated factors were primary determinants of successful eradication of *H. pylori* with furazolidone, amoxicillin-containing quadruple therapy. Furthermore, excluding prior treatment failure, other predictors can potentially be modified during the treatment course to optimize eradicate rate. Our findings highlight the role of physician-patient communication, emphasizing the importance of adherence to prescribed therapy and alcohol cessation during therapy to optimize *H. pylori* eradication.

The strength of our study is the evaluation of a large patient population in a “real-world” setting examining furazolidone, amoxicillin-containing quadruple therapy as both primary and rescue regimens. Furthermore, detailed data of adverse events, as well as, evaluation of factors associated with failed *H. pylori* eradication were analyzed. Finally, our study showed that 14-d furazolidone, amoxicillin-based quadruple therapy led to a high eradication rate regardless of furazolidone dose (*i.e.* 200 mg per day), bismuth dose, or PPI types previously raised as potential factors for successful *H. pylori* eradication[48].

Our study has limitations. Our findings may not be generalizable in areas with highly variable *H. pylori*-resistant patterns or no access to furazolidone. Future studies evaluating the efficacy of furazolidone, amoxicillin-based quadruple therapy in areas other than Iran or China may be invaluable. Furthermore, *H. pylori* culture and sensitivity were not performed in all enrolled patients. However, *H. pylori* antibiotic sensitivity data available in a subset of patients in our study paralleled findings from two recent large studies from the same region[29,49]. Finally, the analysis of patients who completed repeat evaluation of *H. pylori* after treatment may lead to bias in the interpretation of the results.

In conclusion, furazolidone, amoxicillin-based quadruple therapy in a region with high *H. pylori* clarithromycin-resistance demonstrated high eradication rates as primary and rescue therapies with favorable safety profiles. Patient education targeting abstinence from alcohol and strict medication adherence may further optimize *H. pylori* eradication.

**Article Highlights**

***Research background***

With the increase of antibiotic resistance to *Helicobacter pylori* (*H. pylori*) worldwide, traditional triple therapies have become increasingly ineffective. Selecting optimal therapies for antibiotic-resistant *H. pylori* infection has become an important global public health priority.

***Research motivation***

Although studies with limited sample size demonstrate high efficacy of furazolidone-based quadruple therapy for treatment of *H. pylori*, data on the impact of adverse events and predictors of failed *H. pylori* eradication are not well described. Furthermore, evaluating efficacy and safety of furazolidone, amoxicillin-based quadruple therapy for *H. pylori* and identifying predictors of failed eradication in a large patient population are lacking.

***Research objectives***

The aim of the study was to evaluate the outcome of furazolidone, amoxicillin-based quadruple therapy for treatment of *H. pylori* and identify predictors of failed eradication. Furazolidone, amoxicillin-containing quadruple therapy demonstrated high eradication exceeding 90% both as primary and rescue therapies with a favorable safety profile. Patient education targeting abstinence of alcohol use during therapy and strict medication adherence may further optimize *H. pylori* eradication. The results provided a robust evidence for using furazolidone, amoxicillin-containing quadruple as a first-line therapy for *H. pylori* infection in areas with high prevalence of clarithromycin resistance.

***Research methods***

Patients with *H. pylori* infection treated with furazolidone, amoxicillin-based quadruple therapy and received 13C-urea breath test > 4 wk after treatment from January 2015 to December 2015 were evaluated. Patient data including sociodemographic data, prior treatment attempts, medication adherence, and treatment-related adverse events were obtained by reviewing medical records and conducting telephone surveys. *H. pylori* eradication rates for overall and subgroups, treatment-related adverse events, and independent predictors of failed *H. pylori* eradication were evaluated.

***Research results***

Furazolidone, amoxicillin-based quadruple therapy demonstrated high eradication exceeding 90% as both primary and rescue therapies. Fewer than 3% of patients reported treatment-related adverse events leading to premature discontinuation. Poor medication adherence, previous *H. pylori* treatments, and alcohol consumption during therapy were associated with failed *H. pylori* eradication. These findings suggest that furazolidone, amoxicillin-based quadruple therapy with proper patient education could optimize treatment of *H. pylori* infection in regions with high resistance to clarithromycin. Evaluating the efficacy of furazolidone, amoxicillin-based quadruple therapy in areas other than China may be invaluable in future studies.

***Research conclusions***

Furazolidone, amoxicillin-based quadruple therapy demonstrated high eradication rates as both primary and rescue therapies for *H. pylori* infection with a favorable safety profile in areas with high rate of clarithromycin-resistance. Abstinence from alcohol and strict medication adherence during therapy may further optimize *H. pylori* eradication. These findings validate updated guidelines recommending furazolidone-containing quadruple therapy as a first-line regimen for treatment of *H. pylori* infection in populations with high rate of clarithromycin resistance.

***Research perspectives***

Selecting optimal treatment for *H. pylori* infection is important in regions with high rate of resistance to clarithromycin. Targeted patient education may further optimize *H. pylori* eradication. Future study confirming the high efficacy of furazolidone, amoxicillin-based quadruple therapy in areas other than China may be invaluable.

**REFERENCES**

1 **Mandeville KL**, Krabshuis J, Ladep NG, Mulder CJ, Quigley EM, Khan SA. Gastroenterology in developing countries: issues and advances. *World J Gastroenterol* 2009; **15**: 2839-2854 [PMID: 19533805 DOI: 10.3748/wjg.15.2839]

2 **Hunt RH**, Xiao SD, Megraud F, Leon-Barua R, Bazzoli F, van der Merwe S, Vaz Coelho LG, Fock M, Fedail S, Cohen H, Malfertheiner P, Vakil N, Hamid S, Goh KL, Wong BC, Krabshuis J, Le Mair A; World Gastroenterology Organization. Helicobacter pylori in developing countries. World Gastroenterology Organisation Global Guideline. *J Gastrointestin Liver Dis* 2011; **20**: 299-304 [PMID: 21961099]

3 **Zhou L**, Lin S, Ding S, Huang X, Jin Z, Cui R, Meng L, Li Y, Zhang L, Guo C, Xue Y, Yan X, Zhang J. Relationship of Helicobacter pylori eradication with gastric cancer and gastric mucosal histological changes: a 10-year follow-up study. *Chin Med J (Engl)* 2014; **127**: 1454-1458 [PMID: 24762588]

4 **El-Nakeeb A**, Fikry A, Abd El-Hamed TM, Fouda el Y, El Awady S, Youssef T, Sherief D, Farid M. Effect of Helicobacter pylori eradication on ulcer recurrence after simple closure of perforated duodenal ulcer. *Int J Surg* 2009; **7**: 126-129 [PMID: 19138577 DOI: 10.1016/j.ijsu.2008.12.001]

5 **Venerito M**, Krieger T, Ecker T, Leandro G, Malfertheiner P. Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection. *Digestion* 2013; **88**: 33-45 [PMID: 23880479 DOI: 10.1159/000350719]

6 **Luther J**, Higgins PD, Schoenfeld PS, Moayyedi P, Vakil N, Chey WD. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability. *Am J Gastroenterol* 2010; **105**: 65-73 [PMID: 19755966 DOI: 10.1038/ajg.2009.508]

7 **Malfertheiner P**, Bazzoli F, Delchier JC, Celiñski K, Giguère M, Rivière M, Mégraud F; Pylera Study Group. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. *Lancet* 2011; **377**: 905-913 [PMID: 21345487 DOI: 10.1016/S0140-6736(11)60020-2]

8 **Fallone CA**, Chiba N, van Zanten SV, Fischbach L, Gisbert JP, Hunt RH, Jones NL, Render C, Leontiadis GI, Moayyedi P, Marshall JK. The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults. *Gastroenterology* 2016; **151**: 51-69.e14 [PMID: 27102658 DOI: 10.1053/j.gastro.2016.04.006]

9 **Graham DY**, Osato MS, Hoffman J, Opekun AR, Anderson SY, El-Zimaity HM. Furazolidone combination therapies for Helicobacter pylori infection in the United States. *Aliment Pharmacol Ther* 2000; **14**: 211-215 [PMID: 10651662]

10 **Thung I**, Aramin H, Vavinskaya V, Gupta S, Park JY, Crowe SE, Valasek MA. Review article: the global emergence of Helicobacter pylori antibiotic resistance. *Aliment Pharmacol Ther* 2016; **43**: 514-533 [PMID: 26694080 DOI: 10.1111/apt.13497]

11 **Fakheri H**, Bari Z, Aarabi M, Malekzadeh R. Helicobacter pylori eradication in West Asia: a review. *World J Gastroenterol* 2014; **20**: 10355-10367 [PMID: 25132752 DOI: 10.3748/wjg.v20.i30.10355]

12 **Ahmed HH**, El-Aziem SH, Abdel-Wahhab MA. Potential role of cysteine and methionine in the protection against hormonal imbalance and mutagenicity induced by furazolidone in female rats. *Toxicology* 2008; **243**: 31-42 [PMID: 17964703 DOI: 10.1016/j.tox.2007.09.018]

13 **Madrigal-Bujaidar E**, Ibañez JC, Cassani M, Chamorro G. Effect of furazolidone on sister-chromatid exchanges, cell proliferation kinetics, and mitotic index in vivo and in vitro. *J Toxicol Environ Health* 1997; **51**: 89-96 [PMID: 9169063 DOI: 10.1080/00984109708984013]

14 **Ali BH**. Pharmacological, therapeutic and toxicological properties of furazolidone: some recent research. *Vet Res Commun* 1999; **23**: 343-360 [PMID: 10543364]

15 **Jin X**, Tang S, Chen Q, Zou J, Zhang T, Liu F, Zhang S, Sun C, Xiao X. Furazolidone induced oxidative DNA damage via up-regulating ROS that caused cell cycle arrest in human hepatoma G2 cells. *Toxicol Lett* 2011; **201**: 205-212 [PMID: 21195149 DOI: 10.1016/j.toxlet.2010.12.021]

16 **Zullo A**, Ierardi E, Hassan C, De Francesco V. Furazolidone-based therapies for Helicobacter pylori infection: a pooled-data analysis. *Saudi J Gastroenterol* 2012; **18**: 11-17 [PMID: 22249086 DOI: 10.4103/1319-3767.91729]

17 **Buzás GM**, Józan J. Nitrofuran-based regimens for the eradication of Helicobacter pylori infection. *J Gastroenterol Hepatol* 2007; **22**: 1571-1581 [PMID: 17845685 DOI: 10.1111/j.1440-1746.2007.05082.x]

18 **Malfertheiner P**, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, Hunt R, Moayyedi P, Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K, El-Omar EM; European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. *Gut* 2017; **66**: 6-30 [PMID: 27707777 DOI: 10.1136/gutjnl-2016-312288]

19 **Heep M**, Kist M, Strobel S, Beck D, Lehn N. Secondary resistance among 554 isolates of Helicobacter pylori after failure of therapy. *Eur J Clin Microbiol Infect Dis* 2000; **19**: 538-541 [PMID: 10968325]

20 **Liu WZ**, Xie Y, Lu H, Cheng H, Zeng ZR, Zhou LY, Chen Y, Wang JB, Du YQ, Lu NH; Chinese Society of Gastroenterology, Chinese Study Group on Helicobacter pylori and Peptic Ulcer. Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection. *Helicobacter* 2018; **23**: e12475 [PMID: 29512258 DOI: 10.1111/hel.12475]

21 **Fakheri H**, Bari Z, Sardarian H. A modified bismuth-containing quadruple therapy including a short course of furazolidone for Helicobacter pylori eradication after sequential therapy failure. *Helicobacter* 2012; **17**: 264-268 [PMID: 22759325 DOI: 10.1111/j.1523-5378.2012.00946.x]

22 **Song Z**, Suo B, Zhang L, Zhou L. Rabeprazole, Minocycline, Amoxicillin, and Bismuth as First-Line and Second-Line Regimens for Helicobacter pylori Eradication. *Helicobacter* 2016; **21**: 462-470 [PMID: 27060292 DOI: 10.1111/hel.12313]

23 **Safavi M**, Sabourian R, Foroumadi A. Treatment of Helicobacter pylori infection: Current and future insights. *World J Clin Cases* 2016; **4**: 5-19 [PMID: 26798626 DOI: 10.12998/wjcc.v4.i1.5]

24 **Liang X**, Xu X, Zheng Q, Zhang W, Sun Q, Liu W, Xiao S, Lu H. Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study. *Clin Gastroenterol Hepatol* 2013; **11**: 802-7.e1 [PMID: 23376004 DOI: 10.1016/j.cgh.2013.01.008]

25 **Cheng H**, Hu FL. Furazolidone, amoxicillin, bismuth and rabeprazole quadruple rescue therapy for the eradication of Helicobacter pylori. *World J Gastroenterol* 2009; **15**: 860-864 [PMID: 19230048]

26 **Xie Y**, Zhu Y, Zhou H, Lu ZF, Yang Z, Shu X, Guo XB, Fan HZ, Tang JH, Zeng XP, Wen JB, Li XQ, He XX, Ma JH, Liu DS, Huang CB, Xu NJ, Wang NR, Lu NH. Furazolidone-based triple and quadruple eradication therapy for Helicobacter pylori infection. *World J Gastroenterol* 2014; **20**: 11415-11421 [PMID: 25170230 DOI: 10.3748/wjg.v20.i32.11415]

27 **Khademi F**, Poursina F, Hosseini E, Akbari M, Safaei HG. Helicobacter pylori in Iran: A systematic review on the antibiotic resistance. *Iran J Basic Med Sci* 2015; **18**: 2-7 [PMID: 25810869]

28 **Sun QJ**, Liang X, Zheng Q, Gu WQ, Liu WZ, Xiao SD, Lu H. Resistance of Helicobacter pylori to antibiotics from 2000 to 2009 in Shanghai. *World J Gastroenterol* 2010; **16**: 5118-5121 [PMID: 20976850 DOI: 10.3748/wjg.v16.i40.5118]

29 **Shu X**, Yin G, Liu M, Peng K, Zhao H, Jiang M. Antibiotics resistance of Helicobacter pylori in children with upper gastrointestinal symptoms in Hangzhou, China. *Helicobacter* 2018; **23**: e12481 [PMID: 29528162 DOI: 10.1111/hel.12481]

30 **Shiota S**, Reddy R, Alsarraj A, El-Serag HB, Graham DY. Antibiotic Resistance of Helicobacter pylori Among Male United States Veterans. *Clin Gastroenterol Hepatol* 2015; **13**: 1616-1624 [PMID: 25681693 DOI: 10.1016/j.cgh.2015.02.005]

31 **Dore MP**, Lu H, Graham DY. Role of bismuth in improving Helicobacter pylori eradication with triple therapy. *Gut* 2016; **65**: 870-878 [PMID: 26848181 DOI: 10.1136/gutjnl-2015-311019]

32 **Daghaghzadeh H**, Emami MH, Karimi S, Raeisi M. One-week versus two-week furazolidone-based quadruple therapy as the first-line treatment for Helicobacter pylori infection in Iran. *J Gastroenterol Hepatol* 2007; **22**: 1399-1403 [PMID: 17645463 DOI: 10.1111/j.1440-1746.2007.05029.x]

33 **Yuan Y**, Ford AC, Khan KJ, Gisbert JP, Forman D, Leontiadis GI, Tse F, Calvet X, Fallone C, Fischbach L, Oderda G, Bazzoli F, Moayyedi P. Optimum duration of regimens for Helicobacter pylori eradication. *Cochrane Database Syst Rev* 2013; **(12)**: CD008337 [PMID: 24338763 DOI: 10.1002/14651858.CD008337.pub2]

34 **Altamirano A**, Bondani A. Adverse reactions to furazolidone and other drugs. A comparative review. *Scand J Gastroenterol Suppl* 1989; **169**: 70-80 [PMID: 2694347]

35 **Xie LH.** Effect of furazolidone-containing quadruple remedial therapy for Helicobacter pylori eradication: a Meta-analysis. *Guangxi Yixue* 2015; **37**: 606-610.

36 **Hosseini V**, Mokhtare M, Gholami M, Taghvaei T, Maleki I, Valizadeh M, Bari Z, Fakheri H. A Comparison between Moderate- and High-dose Furazolidone in Triple Regimens for Helicobacterpylori Eradication in Iran. *Middle East J Dig Dis* 2014; **6**: 195-202 [PMID: 25349682]

37 **Roghani HS**, Massarrat S, Shirekhoda M, Butorab Z. Effect of different doses of furazolidone with amoxicillin and omeprazole on eradication of Helicobacter pylori. *J Gastroenterol Hepatol* 2003; **18**: 778-782 [PMID: 12795748]

38 **Mokhtare M**, Hosseini V, Tirgar Fakheri H, Maleki I, Taghvaei T, Valizadeh SM, Sardarian H, Agah S, Khalilian A. Comparison of quadruple and triple Furazolidone containing regimens on eradication of helicobacter pylori. *Med J Islam Repub Iran* 2015; **29**: 195 [PMID: 26157713]

39 **Fakheri H**, Merat S, Hosseini V, Malekzadeh R. Low-dose furazolidone in triple and quadruple regimens for Helicobacter pylori eradication. *Aliment Pharmacol Ther* 2004; **19**: 89-93 [PMID: 14687170]

40 **De Francesco V**, Ierardi E, Hassan C, Zullo A. Furazolidone therapy for Helicobacter pylori: is it effective and safe? *World J Gastroenterol* 2009; **15**: 1914-1915 [PMID: 19370795 DOI: 10.3748/wjg.15.1914]

41 **Talebi Bezmin Abadi A**. Furazolidone and Helicobacter pylori Treatment. *Middle East J Dig Dis* 2015; **7**: 110-111 [PMID: 26106473]

42 Some food additives, feed additives and naturally occurring substances. *IARC Monogr Eval Carcinog Risk Chem Hum* 1983; **31**: 1-291 [PMID: 6579000]

43 **Graham DY**, Lu H. Furazolidone in Helicobacter pylori therapy: misunderstood and often unfairly maligned drug told in a story of French bread. *Saudi J Gastroenterol* 2012; **18**: 1-2 [PMID: 22249084 DOI: 10.4103/1319-3767.91724]

44 **Lefebvre M**, Chang HJ, Morse A, van Zanten SV, Goodman KJ; CANHelp Working Group. Adherence and barriers to H. pylori treatment in Arctic Canada. *Int J Circumpolar Health* 2013; **72**: 22791 [PMID: 24416723 DOI: 10.3402/ijch.v72i0.22791]

45 **Shakya Shrestha S**, Bhandari M, Thapa SR, Shrestha R, Poudyal R, Purbey B, Gurung RB. Medication Adherence Pattern and Factors affecting Adherence in Helicobacter Pylori Eradication Therapy. *Kathmandu Univ Med J* 2016; **14**: 58-64 [PMID: 27892443]

46 **Murthy SN**, Dinoso VP Jr, Clearfield HR, Chey WY. Simultaneous measurement of basal pancreatic, gastric acid secretion, plasma gastrin, and secretin during smoking. *Gastroenterology* 1977; **73**: 758-761 [PMID: 892379]

47 **Budzyński J**, Swiatkowski M. [Pathophysiology of the harmful influence of smoking on the course of gastric and duodenal ulcer diseases]. *Przegl Lek* 1996; **53**: 811-815 [PMID: 9173445]

48 **Mohammadi M**, Attaran B, Malekzadeh R, Graham DY. Furazolidone, an Underutilized Drug for H. pylori Eradication: Lessons from Iran. *Dig Dis Sci* 2017; **62**: 1890-1896 [PMID: 28577244]

49 **Ji Z**, Han F, Meng F, Tu M, Yang N, Zhang J. The Association of Age and Antibiotic Resistance of Helicobacter Pylori: A Study in Jiaxing City, Zhejiang Province, China. *Medicine (Baltimore)* 2016; **95**: e2831 [PMID: 26937912]

**P-Reviewer:** Karatapanis S, Tarnawski AS

**S-Editor:** Gong ZM **L-Editor:** **E-Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** China

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): B, B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**Table 1 Baseline demographic and clinical characteristics (*n* = 992) *n* (%)**

|  |  |
| --- | --- |
| **Variable** | **Information** |
| Age (mean age ± SD) | 46.7 ± 12.4 |
| Gender |  |
| Male | 501 (50.5) |
| Female | 491 (49.5) |
| Smoking history | 199/859 (23.2) |
| Alcohol intake history | 231/859 (26.9) |
| Educational level |  |
| < 7 yr | 164 (16.5) |
| 7-9 yr | 249 (25.1) |
| 10-12 yr | 197 (19.9) |
| 13-16 yr | 229 (23.1) |
| >16 yr | 20 (2.0) |
| Unknown | 133 (13.4) |
| Diagnosis |  |
| Functional dyspepsia | 478 (48.2) |
| Peptic ulcers | 259 (26.1) |
| Erosive esophagitis | 69 (7.0) |
| Other sources of upper GI bleeding | 5 (0.5) |
| Gastric tumors | 6 (0.6) |
| Asymptomatic gastritis | 75 (7.6) |
| 13C-UBT positive during health checkup | 100 (10.1) |
| Times |  |
| First | 842 (84.9) |
| Second | 127 (12.8) |
| Third or more | 23 (2.3) |
| PPI type |  |
| Esomeprazole | 264 (26.6) |
| Rabeprazole | 224 (22.6) |
| Pantoprazole | 435 (43.9) |
| Other PPIs | 69 (7.0) |
| Bismuth dose |  |
| 400 mg per day | 213 (21.5) |
| 600 mg per day | 391 (39.4) |
| 800 mg per day | 388 (39.1) |
| Regimen |  |
| 14-d regimen | 971 (97.9) |
| 10-d regimen | 21 (2.1) |

GI: Gastrointestinal; PPI: Proton pump inhibitor; 13C-UBT: 13C-urea breath test.

**Table 2** ***Helicobacter pylori* eradication rates with furazolidone, amoxicillin-based quadruple therapy: overall and by subgroups % (95%CI)**

|  |  |  |
| --- | --- | --- |
| **Variable** | **n/N** | **Eradication rate** |
| Overall | 937/992 | 94.5 (94.1-95.9) |
| Times |  |  |
| Primary | 800/842 | 95.0 (93.5-96.5) |
| Rescue | 137/150 | 91.3 (86.8-95.8) |
| Adverse events1 |  |  |
| Without | 683/715 | 95.5 (94.0-97.0)2 |
| With | 130/144 | 90.3 (85.5-95.1) |

1Patients who completed the study protocol were divided into two groups: without or with adverse events during therapy. Eradication rates of two groups were calculated and the difference between the two groups were analyzed. 2Eradication rates were higher among patients without (mean difference = 5.2%, 95%CI: 0.7%-11.7%, *P =* 0.01) compared to those with adverse events during therapy. n: Number of successful eradication; N: Number of total patients.

**Table 3** **Adverse events of furazolidone, amoxicillin-based quadruple therapy (*n* = 859) *n* (%)**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Adverse events** | **Number** | **Severe** | | **Impact on treatment** | **Eradication** |
| Abdominal discomfort | 39 (4.5) | | — | 2 stopped prior to completion (10, 12 d) | 38 (97.4) |
| Dizziness | 11(1.3) | | 2 (0.2) | 3 stopped prior to completion (7, 10, 10, 12 d);  1 experienced dizziness after drinking alcohol and stopped prior to completion (10 d); 1 took 50% medicine | 10 (90.9) |
| Nausea (with or without vomiting) | 20 (2.3) | | — | 1 took 75% medicine | 16 (80.0) |
| Fatigue | 11 (1.3) | | 1 (0.1) | 1 stopped prior to completion (12 d);  1 changed to traditional Chinese medicine during therapy (7 d) | 9 (81.8) |
| Anorexia | 13 (1.5) | | — | 1 took 80% medicine | 13 (100) |
| Skin rash/pruritus | 18 (2.1) | | 3 (0.4) | 4 stopped prior to completion (4, 7, 10, 11 d); 2 changed to other regimens during therapy (2, 10 d); 1 took half of amoxicillin and all other drugs | 15 (83.3) |
| Fever | 2 (0.2) | | 2 (0.2) | 2 stopped prior to completion (7, 9 d) | 2 (100) |
| Diarrhea | 9 (1.1) | | 1 (0.1) | 1 stopped prior to completion (less than 7 d) | 8 (88.9) |
| Constipation | 3 (0.4) | | — | — | 3 (100) |
| Flatulence | 2 (0.2) | | — | — | 2 (100) |
| Muscle pain or spasm (shoulder and back) | 3 (0.4) | | — | — | 1 (33.3) |
| Acid regurgitation | 1 (0.1) | | — | — | 1 (100) |
| Abdominal pain | 4 (0.5) | | 1 (0.1) | 2 stopped prior to completion (7,10 d) | 4 (100) |
| Weight loss | 3 (0.4) | | — | — | 3 (100) |
| Bitter taste & dry throat | 2 (0.2) | | — | 1 took 75% medicine | 2 (100) |
| Belching | 1 (0.1) | | — | — | 1 (100) |
| Chest congestion | 1 (0.1) | | — | — | 1 (100) |
| Heartburn | 1 (0.1) | | — | — | 1 (100) |
| Total | 144 (16.8) | | 10 (1.2) | 24 (2.8) | 130 (90.3%) |

**Table 4** **Univariate and multivariate analyses for predictors of failed *Helicobacter pylori* eradication**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Factors** | | **Eradication rate**  **n/N (%)** | ***P* value1** | **Multivariate2** | |
| **OR (95%CI)** | ***P* value** |
| Age (yr) | < 60 | 781/827 (94.4) | 0.96 | — | — |
| * 60 | 156/165 (94.5) |  |  |  |
| Gender | Male | 469/501 (93.6) | 0.24 | — | — |
| Female | 468/491 (95.3) |  |  |  |
| Education2 | < 7 yr | 150/164 (91.5) | 0.29 | — | — |
| 7-9 yr | 237/249 (95.2) |  |  |  |
| 10-12 yr | 187/197 (94.9) |  |  |  |
| 13-16 yr | 219/229 (95.6) |  |  |  |
| >16 yr | 20/20 (100) |  |  |  |
| Times | First | 800/842 (95.0) | 0.002 | Reference | — |
| Second | 119/127 (93.7) |  | 1.2 (0.5-2.7) | 0.73 |
| Third or more | 18/23 (78.3) |  | 7.4 (2.2-24.9) | 0.001 |
| Diagnosis | Functional dyspepsia | 453/478 (94.8) | 0.49 | — | — |
| Peptic ulcers | 245/259 (97.1) |  |  |  |
| Erosive esophagitis | 67/69 (97.1) |  |  |  |
| Other sources of upper GI bleeding | 4/5 (80.0) |  |  |  |
| Gastric neoplasm | 6/6 (100.0) |  |  |  |
| Asymptomatic gastritis | 68/75 (90.7) |  |  |  |
| 13C-UBT positive during health checkup | 94/100 (94.0) |  |  |  |
| PPI type | Esomeprazole | 253/264 (95.8) | 0.42 | — | — |
| Rabeprazole | 209/224 (93.3) |  |  |  |
| Pantoprazole | 408/435 (93.8) |  |  |  |
| Other PPIs | 67/69 (97.1) |  |  |  |
| Bismuth | 400 mg per day | 204/213 (95.8) | 0.40 | — | — |
| 600 mg per day | 371/391 (94.9) |  |  |  |
| 800 mg per day | 362/388 (93.3) |  |  |  |
| Course | 10 d | 19/21 (90.5) | 0.33 | — | — |
| 14 d | 918/971 (94.5) |  |  |  |
| Adherence2 | Took 80% medicine or more | 782/819 (96.2) | < 0.001 | Reference | — |
| Took less than 80% medicine | 31/40 (77.5) |  | 6.7 (2.8-15.8) | < 0.001 |
| Smoking2 | Non-smoker | 631/660 (95.6) | 0.004 | Reference | — |
| Abstinence during therapy | 77/80 (96.3) |  | 0.7 (0.2-2.7) | 0.65 |
| Smoking during therapy | 105/119 (88.2) |  | 1.9 (0.9-4.3) | 0.10 |
| Alcohol2 | Non-alcohol user | 600/628 (95.5) | <0.001 | Reference | — |
| Abstinent during therapy | 186/197(94.4) |  | 1.0 (0.4-2.3) | 1.00 |
| Alcohol during therapy | 27/34 (79.4) |  | 4.4 (1.5-12.3) | 0.008 |

1One factor analysis; 2Data only analyzed by patients completed the study protocol (*n* = 859). n: Number of successful eradication; N: Number of total patients; GI: Gastrointestinal; PPI: Proton pump inhibitor; 13C-UBT: 13C-urea breath test.